Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for people living with neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co.'s main growth areas include multiple sclerosis (MS) and neuroimmunology; Alzheimer's disease and dementia; neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis; movement disorders, including Parkinson's disease; and ophthalmology. Co.'s marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We show 42 historical shares outstanding datapoints in our BIIB shares outstanding history coverage, used to compute BIIB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BIIB market cap history over the course of time is important for investors
interested in comparing BIIB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BIIB versus a peer is one thing; comparing
BIIB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BIIB can fluctuate over the course of history.
With this page we aim to empower investors researching BIIB by allowing them to research the BIIB market cap history. |
Video: The Importance of Market Cap
